Study titled, "bridging the GAP between urinary tract infection pharmacokinetic/pharmacodynamic in vitro models and the optimization of antibiotic selection, dosing strategies, clinical breakpoints,…

Active Definitive Contract Awarded Last action

Contract number
75F40123C00185
Awardee
Awarding agency
Obligated
$399,988

Award facts

Opportunity
Contract value 100% obligated
$399,988.00 Current and potential, with all options
Completion date 84% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Australia
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00004 $0
Supplemental Agreement for work within scope P00003 $0
Other Administrative Action P00002 $0
Change Order P00001 $0
Original award $399,988

About this award

The Food and Drug Administration awarded a $399,988 cost-plus-no-fee definitive contract to Monash University on September 25, 2023, to conduct advanced research titled "Bridging the Gap Between Urinary Tract Infection Pharmacokinetic/Pharmacodynamic In Vitro Models and the Optimization of Antibiotic Selection, Dosing Strategies, Clinical Breakpoints, and Novel Drug Development." The contract will be performed in Australia and is scheduled for completion by June 28, 2027. This award emerged from the FDA's Broad Agency Announcement solicitation posted in November 2022, which sought proposals addressing regulatory science and innovation in product development, post-market surveillance, and public health preparedness. The contract does not carry a set-aside designation and was awarded on the basis of technical merit and research capabilities.

Monash University, an international non-profit research institution based in Victoria, Australia, is well-positioned to execute this work given its extensive track record performing sophisticated scientific research for multiple U.S. federal agencies. The university's prior federal contract portfolio includes substantial biomedical and advanced technology projects for the Department of Defense, National Institutes of Health, and the Defense Advanced Research Projects Agency, demonstrating established expertise in complex research execution. This FDA contract focuses on developing improved in vitro pharmacokinetic and pharmacodynamic models to optimize antibiotic selection and dosing strategies for urinary tract infections, which directly supports the agency's regulatory science mission to enhance drug development and clinical decision-making.

Description

Study titled, "bridging the GAP between urinary tract infection pharmacokinetic/pharmacodynamic in vitro models and the optimization of antibiotic selection, dosing strategies, clinical breakpoints, and novel drug development." FY23C3BWP10.

Quick answers

Who was awarded contract 75F40123C00185?

75F40123C00185 was awarded to Monash University by Food and Drug Administration (Department of Health and Human Services) on September 25, 2023.

How much is contract 75F40123C00185 worth?

The government has obligated $399,988 on 75F40123C00185.

Was contract 75F40123C00185 competed?

The extent of competition for 75F40123C00185 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award